DK175835B1 - Fremgangsmåde til fremstilling af en sammensætning, der omfatter en konjugation af 15A8-antistof - Google Patents
Fremgangsmåde til fremstilling af en sammensætning, der omfatter en konjugation af 15A8-antistof Download PDFInfo
- Publication number
- DK175835B1 DK175835B1 DK199100010A DK1091A DK175835B1 DK 175835 B1 DK175835 B1 DK 175835B1 DK 199100010 A DK199100010 A DK 199100010A DK 1091 A DK1091 A DK 1091A DK 175835 B1 DK175835 B1 DK 175835B1
- Authority
- DK
- Denmark
- Prior art keywords
- conjugation
- antibody
- preparing
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/44—Antibodies bound to carriers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57411—Specifically defined cancers of cervix
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57469—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving tumor associated glycolinkage, i.e. TAG
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21659588A | 1988-07-07 | 1988-07-07 | |
PCT/US1989/002919 WO1990000405A1 (en) | 1988-07-07 | 1989-06-29 | Immunoconjugates for cancer diagnosis and therapy |
Publications (3)
Publication Number | Publication Date |
---|---|
DK1091A DK1091A (da) | 1991-01-04 |
DK1091D0 DK1091D0 (da) | 1991-01-04 |
DK175835B1 true DK175835B1 (da) | 2005-03-21 |
Family
ID=22807704
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK199100010A DK175835B1 (da) | 1988-07-07 | 1991-01-04 | Fremgangsmåde til fremstilling af en sammensætning, der omfatter en konjugation af 15A8-antistof |
Country Status (18)
Country | Link |
---|---|
US (1) | US6669938B1 (no) |
EP (2) | EP0423228B1 (no) |
JP (1) | JP2756329B2 (no) |
KR (1) | KR0152272B1 (no) |
AU (1) | AU636113B2 (no) |
CA (1) | CA1336497C (no) |
DE (1) | DE68912334T2 (no) |
DK (1) | DK175835B1 (no) |
ES (1) | ES2059759T3 (no) |
FI (1) | FI102517B1 (no) |
HK (1) | HK1006676A1 (no) |
IE (1) | IE62463B1 (no) |
IL (1) | IL90688A (no) |
NO (1) | NO303122B1 (no) |
NZ (1) | NZ229652A (no) |
PT (1) | PT91075B (no) |
WO (1) | WO1990000405A1 (no) |
ZA (1) | ZA894665B (no) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE63847B1 (en) * | 1989-05-05 | 1995-06-14 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
US5314995A (en) * | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
ZA912490B (en) * | 1990-04-19 | 1992-12-30 | Res Dev Foundation | Antibody conjugates for treatment of neoplastic disease |
IE912716A1 (en) * | 1990-08-14 | 1992-02-26 | Res Dev Foundation | Protein Structure of the Plant Toxin Gelonin |
US5194594A (en) * | 1990-09-07 | 1993-03-16 | Techniclone, Inc. | Modified antibodies |
US6599505B1 (en) | 1992-04-10 | 2003-07-29 | Research Development Foundation | Immunotoxins directed against CD33 related surface antigens |
ZA932523B (en) * | 1992-04-10 | 1994-10-08 | Res Dev Foundation | Immunotoxins directed against cd33 related surface antigens |
SE9601158D0 (sv) * | 1996-03-26 | 1996-03-26 | Stefan Svenson | Method of producing immunogenic products and vaccines |
IT1286663B1 (it) * | 1996-06-27 | 1998-07-15 | Ministero Uni Ricerca Scient E | Proteina capace di inibire l'attivita' ribosomiale,sua preparazione ed uso come immunoconiugato chimico o ricombinante e sequenza di cdna |
AU763719B2 (en) | 1997-12-08 | 2003-07-31 | Merck Patent Gmbh | Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation |
SK782002A3 (en) | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
CA2380331C (en) | 1999-08-09 | 2012-11-20 | Lexigen Pharmaceuticals Corp. | Multiple cytokine-antibody complexes |
CA2399832C (en) | 2000-02-11 | 2011-09-20 | Stephen D. Gillies | Enhancing the circulating half-life of antibody-based fusion proteins |
ZA200305980B (en) | 2001-02-12 | 2007-01-31 | Res Dev Foundation | Modified proteins, designer toxins, and methods of making thereof |
KR20090010127A (ko) | 2001-03-07 | 2009-01-28 | 메르크 파텐트 게엠베하 | 하이브리드 이소타입 항체 부분구조를 포함하는 단백질을 위한 발현 기술 |
WO2002079415A2 (en) | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
DE60239454D1 (de) | 2001-05-03 | 2011-04-28 | Merck Patent Gmbh | Rekombinanter, tumorspezifischer antikörper und dessen verwendung |
US7101977B2 (en) | 2001-07-17 | 2006-09-05 | Research Development Foundation | Therapeutic agents comprising pro-apoptotic proteins |
PT1454138E (pt) | 2001-12-04 | 2012-03-28 | Merck Patent Gmbh | Imunocitoquinas com seletividade modulada |
CN1662254A (zh) * | 2002-05-03 | 2005-08-31 | 雷文生物技术公司 | Alcam和alcam调制剂 |
AU2003275985A1 (en) * | 2002-06-12 | 2003-12-31 | Research Development Foundation | Immunotoxin as a therapeutic agent and uses thereof |
RU2366664C2 (ru) | 2002-12-17 | 2009-09-10 | Мерк Патент Гмбх | Гуманизированное антитело (н14.18) на основании антитела 14.18 мыши, связывающееся с gd2, и его слияние с il-2 |
EP1699822B1 (en) | 2003-12-30 | 2008-04-23 | MERCK PATENT GmbH | Il-7 fusion proteins with antibody portions, their preparation and their use |
EP1702069A2 (en) | 2004-01-05 | 2006-09-20 | EMD Lexigen Research Center Corp. | Interleukin-12 targeted to oncofoetal fibronectin |
US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
JP2008528633A (ja) * | 2005-02-01 | 2008-07-31 | リサーチ ディベロップメント ファウンデーション | Blysレセプターを標的化するためのblys融合タンパク質およびb細胞増殖性疾患の処置方法 |
WO2008031767A1 (en) * | 2006-09-12 | 2008-03-20 | Dkfz Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts | Cell culture of keratinocytes under non-differentiating conditions |
GB0718045D0 (en) * | 2007-09-14 | 2007-10-24 | Peptcell Ltd | Pharmaceutical compound |
JP5781501B2 (ja) | 2009-04-22 | 2015-09-24 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | 改変されたFcRn結合部位を有する抗体融合タンパク質 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4263279A (en) * | 1975-08-19 | 1981-04-21 | Yeda Research & Development Co. Ltd | Pharmaceutically active compositions containing adriamycin and daunomycin |
US4440747A (en) | 1980-09-30 | 1984-04-03 | The United States Of America As Represented By The Department Of Health And Human Services | Monoclonal antibody-ricin hybrids as a treatment of murine graft-versus-host disease |
US4520226A (en) | 1982-07-19 | 1985-05-28 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of graft versus host disease using a mixture of T-lymphocyte specific monoclonal antibody: ricin conjugates |
GB2131830A (en) | 1982-12-10 | 1984-06-27 | Ludwig Inst Cancer Res | Monoclonal antibody for use against breast cancer |
FR2546756B1 (fr) * | 1983-06-03 | 1985-11-29 | Centre Nat Rech Scient | Nouveaux derives immunostimulants, leur preparation et leur application comme medicament |
GB2148299B (en) * | 1983-09-01 | 1988-01-06 | Hybritech Inc | Antibody compositions of therapeutic agents having an extended serum half-life |
DK423483A (da) | 1983-09-16 | 1985-03-17 | Nordisk Laederforskningsraad | Fremgangsmaade til maerkning af huder, skind og lignende arkformige materialer |
US4753894A (en) * | 1984-02-08 | 1988-06-28 | Cetus Corporation | Monoclonal anti-human breast cancer antibodies |
DE3408463C2 (de) * | 1984-03-08 | 1987-02-26 | Giulini Chemie Gmbh, 6700 Ludwigshafen | Verfahren zur Herstellung einer aluminium- und magnesiumhaltigen Verbindung der Formel Al↓5↓Mg↓1↓↓0↓ (OH)↓3↓↓1↓ (SO↓4↓)↓2↓ . x H↓2↓O |
EP0184369B1 (en) * | 1984-12-05 | 1992-04-01 | The Salk Institute For Biological Studies | Monoclonal antibody specific for a mammary tumor cell surface antigen |
WO1986005098A1 (en) * | 1985-03-04 | 1986-09-12 | Dana-Farber Cancer Institute, Inc. | Immunotoxin and method of making |
DE3676670D1 (de) * | 1985-06-26 | 1991-02-07 | Cetus Corp | Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung. |
JPS6220909A (ja) | 1985-07-17 | 1987-01-29 | 株式会社井上ジャパックス研究所 | パイプ等の接合方法 |
FR2587332B1 (fr) | 1985-09-19 | 1989-02-17 | Rhone Poulenc Spec Chim | Procede de chloration selective de composes phenoliques |
ATE76583T1 (de) | 1985-12-06 | 1992-06-15 | Cetus Corp | Anti-immuntoxine gegen menschlichen eierstockkrebs und verfahren zu deren verwendung. |
US4831122A (en) * | 1986-01-09 | 1989-05-16 | Regents Of The University Of Minnesota | Radioimmunotoxins |
EP0256471A3 (en) | 1986-08-15 | 1989-10-25 | Xoma Corporation | Cytotoxic conjugates for cancer therapy |
US4771128A (en) * | 1986-10-10 | 1988-09-13 | Cetus Corporation | Method of purifying toxin conjugates using hydrophobic interaction chromatography |
-
1989
- 1989-06-16 IE IE197089A patent/IE62463B1/en not_active IP Right Cessation
- 1989-06-20 IL IL9068889A patent/IL90688A/en unknown
- 1989-06-20 ZA ZA894665A patent/ZA894665B/xx unknown
- 1989-06-21 NZ NZ229652A patent/NZ229652A/xx unknown
- 1989-06-29 DE DE89908605T patent/DE68912334T2/de not_active Expired - Lifetime
- 1989-06-29 AU AU39761/89A patent/AU636113B2/en not_active Expired
- 1989-06-29 WO PCT/US1989/002919 patent/WO1990000405A1/en active IP Right Grant
- 1989-06-29 JP JP1508040A patent/JP2756329B2/ja not_active Expired - Fee Related
- 1989-06-29 KR KR1019900700479A patent/KR0152272B1/ko not_active IP Right Cessation
- 1989-06-29 EP EP89908605A patent/EP0423228B1/en not_active Expired - Lifetime
- 1989-07-03 EP EP89306713A patent/EP0350230B1/en not_active Expired - Lifetime
- 1989-07-03 ES ES89306713T patent/ES2059759T3/es not_active Expired - Lifetime
- 1989-07-06 CA CA000604974A patent/CA1336497C/en not_active Expired - Fee Related
- 1989-07-06 PT PT91075A patent/PT91075B/pt not_active IP Right Cessation
-
1991
- 1991-01-04 FI FI910049A patent/FI102517B1/fi active
- 1991-01-04 DK DK199100010A patent/DK175835B1/da not_active IP Right Cessation
- 1991-01-04 NO NO910031A patent/NO303122B1/no not_active IP Right Cessation
-
1993
- 1993-09-24 US US08/201,134 patent/US6669938B1/en not_active Expired - Fee Related
-
1998
- 1998-06-23 HK HK98106033A patent/HK1006676A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP0350230B1 (en) | 1993-09-15 |
ZA894665B (en) | 1990-04-25 |
KR900701321A (ko) | 1990-12-01 |
US6669938B1 (en) | 2003-12-30 |
FI102517B (fi) | 1998-12-31 |
CA1336497C (en) | 1995-08-01 |
NZ229652A (en) | 1991-08-27 |
NO910031L (no) | 1991-01-04 |
IE891970L (en) | 1990-01-07 |
IL90688A (en) | 1995-03-30 |
EP0350230A3 (en) | 1990-12-12 |
EP0350230A2 (en) | 1990-01-10 |
DE68912334D1 (de) | 1994-02-24 |
EP0423228A1 (en) | 1991-04-24 |
DK1091A (da) | 1991-01-04 |
WO1990000405A1 (en) | 1990-01-25 |
HK1006676A1 (en) | 1999-03-12 |
EP0423228A4 (en) | 1991-07-17 |
IE62463B1 (en) | 1995-02-08 |
FI102517B1 (fi) | 1998-12-31 |
FI910049A0 (fi) | 1991-01-04 |
KR0152272B1 (ko) | 1998-10-15 |
PT91075B (pt) | 1995-01-31 |
DK1091D0 (da) | 1991-01-04 |
ES2059759T3 (es) | 1994-11-16 |
NO303122B1 (no) | 1998-06-02 |
JP2756329B2 (ja) | 1998-05-25 |
IL90688A0 (en) | 1990-01-18 |
JPH04500510A (ja) | 1992-01-30 |
PT91075A (pt) | 1990-02-08 |
DE68912334T2 (de) | 1994-05-05 |
EP0423228B1 (en) | 1994-01-12 |
AU636113B2 (en) | 1993-04-22 |
AU3976189A (en) | 1990-02-05 |
NO910031D0 (no) | 1991-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK175835B1 (da) | Fremgangsmåde til fremstilling af en sammensætning, der omfatter en konjugation af 15A8-antistof | |
DK594588D0 (da) | Fremgangsmaade til fremstilling af et kimaerisk antistofmolekyle | |
DK0429760T4 (da) | Fremgangsmåde til fremstilling af et aromatiseringsmiddel | |
DK0428758T3 (da) | Fremgangsmåde til fremstilling af et albuminpræparat | |
DK65185D0 (da) | Fremgangsmaade til fremstilling af antistof | |
DK161788A (da) | Fremgangsmaade til fremstilling af zidovudin | |
DK200489D0 (da) | Fremgangsmaade til fremstilling af polypeptider | |
DK343089D0 (da) | Fremgangsmaade til fremstilling af loebeost | |
DK161705C (da) | Fremgangsmaade til fremstilling af et 13-hydroxy-5-ketomilbemycinderivat | |
DK19889D0 (da) | Fremgangsmaade til fremstilling af polypeptider | |
DK389484D0 (da) | Fremgangsmaade til fremstilling af 2,3-dihydrobenzopyranonderivater | |
DK75487A (da) | Fremgangsmaade til fremstilling af et butanonderivat | |
DK0377437T3 (da) | Fremgangsmåde til fremstilling af 2,4-diamino-6-piperidinylpyrimidin-3-N-oxid | |
DK75087D0 (da) | Fremgangsmaade til fremstilling af et butanonderivat | |
DK27988A (da) | Fremgangsmaade til fremstilling af substituerede benzaldehyder | |
DK75287D0 (da) | Fremgangsmaade til fremstilling af et butanonderivat | |
DK74987D0 (da) | Fremgangsmaade til fremstilling af et butanonderivat | |
DK84987D0 (da) | Kontinuerlig fremgangsmaade til fremstilling af o,o-di-la-vere-alkylchlorthiophosphat | |
DK150695C (da) | Fremgangsmaade til fremstilling af en broedforbedrende komposition | |
DK4988A (da) | Fremgangsmaade til fremstilling af alkoxyalkylidenhydrazinopyridazinderivater | |
DK75187A (da) | Fremgangsmaade til fremstilling af et butanonderivat | |
DK142387D0 (da) | Fremgangsmaade til fremstilling af et butanonderivat | |
DK75387D0 (da) | Fremgangsmaade til fremstilling af et butanonderivat | |
DK433689A (da) | Fremgangsmaade til fremstilling af 2-n-propyl-4-amino-5-methoxy-methylpyrimidin | |
DK226088D0 (da) | Fremgangsmaade til fremstilling af 3-hydrocarbyl-3-cephemderivater |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUP | Patent expired |